Merck Prefers Its Own Approach Over Joining The Tax-Inversion Wave
This article was originally published in The Pink Sheet Daily
Executive Summary
While awaiting potential big revenues from late-stage oncology and HCV candidates, Merck says it won’t join competitors in pursuing a major M&A deal to obtain the tax benefits of foreign domicile. Smaller, targeted transactions like the about-to-close buyout of Idenix fit better with the pharma’s strategy, CEO Frazier says.